Compare GSK plc (GSK) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Annaly Capital Management, Inc. — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Annaly Capital Management, Inc. trades at $18.31 (market cap $13.77B). The key difference: GSK plc is far larger — about 6.7× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays the higher dividend (16.42%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Annaly Capital Management, Inc. for 91 Days on average.
| GSK | NLY | |
|---|---|---|
Market Cap | $91.88B | $13.77B |
Volume | 7,730,529 | 21,283,879 |
Sector | Health | Real Estate |
52-Week High | $61.18 | $24.40 |
52-Week Low | $43.24 | $17.93 |
Typical Hold Time | 93 Days | 91 Days |
Enterprise Value | $111.88B | $135.80B |
Dividend Yield | 3.9% | 16.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
NLY trades at $18.30, up 2.06% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows strong profitability with a 92.77% net income margin and a low P/E of 4.41. Recent earnings have consistently beaten estimates, and the company maintains a high dividend yield near 15%, supported by a $0.75 quarterly payout announced for Q3 2026.
The outlook is mixed: attractive valuation and high yield offer upside potential, but significant cash flow volatility and rising debt-to-asset ratio pose risks. Analyst consensus is bullish with a $22.00 price target, yet technical weakness and interest rate sensitivity warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
